Literature DB >> 16455939

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.

Daniel J Skiest1.   

Abstract

Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16455939      PMCID： PMC1392696          DOI： 10.1128/JCM.44.2.655-656.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  5 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

3.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 4.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Authors:  Judith N Steenbergen; Jeff Alder; Grace M Thorne; Francis P Tally
Journal:  J Antimicrob Chemother       Date:  2005-02-10       Impact factor: 5.790

5.  The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.

Authors:  S S Richter; D E Kealey; C T Murray; K P Heilmann; S L Coffman; G V Doern
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790
  5 in total
  62 in total

1.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.

Authors:  Rym Boudjemaa; Clément Cabriel; Florence Dubois-Brissonnet; Nicolas Bourg; Guillaume Dupuis; Alexandra Gruss; Sandrine Lévêque-Fort; Romain Briandet; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  The potential economic value of a Staphylococcus aureus vaccine for neonates.

Authors:  Bruce Y Lee; Paul J Ufberg; Rachel R Bailey; Ann E Wiringa; Kenneth J Smith; Andrew J Nowalk; Conor Higgins; Angela R Wateska; Robert R Muder
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

5.  The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance?

Authors:  Cristina El Haj; Oscar Murillo; Alba Ribera; Dolors Garcia-Somoza; Fe Tubau; Carmen Cabellos; Javier Cabo; Javier Ariza
Journal:  Med Microbiol Immunol       Date:  2016-09-17       Impact factor: 3.402

6.  Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.

Authors:  Noreen H Chan Tompkins; Stephen J Harnicar
Journal:  P T       Date:  2008-05

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.

Authors:  Anu Daniel; Chad Euler; Mattias Collin; Peter Chahales; Kenneth J Gorelick; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

Authors:  B A Cunha; F M Pherez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

10.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.